Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

CymaBay Announces FDA Accepted NDA For Seladelpar For Primary Biliary Cholangitis; FDA Grants Priority Review

Author: Benzinga Newsdesk | February 12, 2024 08:47am

FDA has granted Priority Review with a target PDUFA date of August 14 -

Posted In: CBAY

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist